Quick Answer
MapLight Therapeutics, Inc. reported Net Income of -$161.15 million for fiscal year 2025.
MapLight Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net Income | -$161.15M -107.7% |
-$77.58M | — |
| Diluted EPS | -$18.56 +82.4% |
-$105.38 | — |
| Total Assets | $479.51M +250.2% |
$136.92M | — |
| Cash and Equivalents | $46.73M +22.2% |
$38.25M | — |
| Stockholders Equity | $458.37M +336.7% |
-$193.63M -64.7% |
-$117.58M |
| R&D Expense | $138.35M +101.9% |
$68.52M | — |
| Operating Income | -$169.08M -103.8% |
-$82.95M | — |
| Shares Outstanding | 44.02M +5682.9% |
761,276 | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$29.42M | -54.7% | +1.4% |
| Diluted EPS | September 30, 2025 | -$37.18 | -48.2% | -48.2% |
| Total Assets | September 30, 2025 | $257.22M | — | +87.9% |
| Cash and Equivalents | September 30, 2025 | $64.15M | — | +67.7% |
| Stockholders Equity | September 30, 2025 | -$274.18M | -59.1% | -11.9% |
| R&D Expense | September 30, 2025 | $27.09M | +61.1% | +61.1% |
| Operating Income | September 30, 2025 | -$31.50M | -50.8% | -50.8% |
| Shares Outstanding | September 30, 2025 | 808,015 | — | +6.1% |
- MapLight Therapeutics, Inc. reported Net Income of -$161.15 million for fiscal year 2025.
- MapLight Therapeutics, Inc. showed a decrease of -107.7% in Net Income compared to the prior fiscal year.
- MapLight Therapeutics, Inc. reported Diluted EPS of $18.56 per share (loss) for fiscal year 2025.
- MapLight Therapeutics, Inc. showed an increase of +82.4% in Diluted EPS compared to the prior fiscal year.
- MapLight Therapeutics, Inc. reported Total Assets of $479.51 million for fiscal year 2025.
- MapLight Therapeutics, Inc. showed an increase of +250.2% in Total Assets compared to the prior fiscal year.
- MapLight Therapeutics, Inc. reported Cash and Equivalents of $46.73 million for fiscal year 2025.
- MapLight Therapeutics, Inc. showed an increase of +22.2% in Cash and Equivalents compared to the prior fiscal year.
- MapLight Therapeutics, Inc. reported Stockholders Equity of $458.37 million for fiscal year 2025.
- MapLight Therapeutics, Inc. showed an increase of +336.7% in Stockholders Equity compared to the prior fiscal year.
- MapLight Therapeutics, Inc. reported R&D Expense of $138.35 million for fiscal year 2025.
- MapLight Therapeutics, Inc. showed an increase of +101.9% in R&D Expense compared to the prior fiscal year.
- MapLight Therapeutics, Inc. reported Operating Income of -$169.08 million for fiscal year 2025.
- MapLight Therapeutics, Inc. showed a decrease of -103.8% in Operating Income compared to the prior fiscal year.
- MapLight Therapeutics, Inc. reported Shares Outstanding of 44.02 million shares for fiscal year 2025.
- MapLight Therapeutics, Inc. showed an increase of +5682.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: